We are live on ! Find out more
BMY icon

Bristol-Myers Squibb

1,523 hedge funds and large institutions have $63.3B invested in Bristol-Myers Squibb in 2016 Q3 according to their latest regulatory filings, with 110 funds opening new positions, 663 increasing their positions, 548 reducing their positions, and 147 closing their positions.

New
Increased
Maintained
Reduced
Closed

21% more repeat investments, than reductions

Existing positions increased: 663 | Existing positions reduced: 548

3.14% less ownership

Funds ownership: 73.94%70.8% (-3.1%)

3% less funds holding

Funds holding: 1,5771,523 (-54)

17% less call options, than puts

Call options by funds: $1.15B | Put options by funds: $1.38B

25% less first-time investments, than exits

New positions opened: 110 | Existing positions closed: 147

30% less capital invested

Capital invested by funds: $90.9B → $63.3B (-$27.6B)

55% less funds holding in top 10

Funds holding in top 10: 11049 (-61)

Holders
1,523
Holders Change
-54
Holders Change %
-3.42%
% of All Funds
40.62%
Holding in Top 10
49
Holding in Top 10 Change
-61
Holding in Top 10 Change %
-55.45%
% of All Funds
1.31%
New
110
Increased
663
Reduced
548
Closed
147
Calls
$1.15B
Puts
$1.38B
Net Calls
-$227M
Net Calls Change
-$366M
Name Holding Trade Value Shares
Change
Change in
Stake
PAM
326
Private Asset Management
California
$9.66M +$715K +11,135 +7%
TCM
327
Twin Capital Management
Pennsylvania
$9.56M +$2.48M +38,610 +28%
HP
328
Hosking Partners
United Kingdom
$9.51M +$1.36M +21,112 +14%
EAM
329
Edge Asset Management
Washington
$9.49M -$11.3M -175,728 -50%
BSA
330
Braun Stacey Associates
New York
$9.46M -$5.55M -86,392 -33%
CRC
331
Curi RMB Capital
Illinois
$9.43M +$3.04M +47,295 +37%
NB
332
Norinchukin Bank
Japan
$9.37M +$111K +1,732 +1%
ISL
333
Ingalls & Snyder LLC
New York
$9.35M +$1.04M +16,125 +10%
Cambridge Investment Research Advisors
334
Cambridge Investment Research Advisors
Iowa
$9.31M +$1.08M +16,737 +11%
OPERF
335
Oregon Public Employees Retirement Fund
Oregon
$9.3M -$4.36M -67,828 -28%
BG
336
Bollard Group
Massachusetts
$9.24M +$43.5K +677 +0.4%
JSP
337
Jackson Square Partners
California
$9.18M +$4.28M +66,637 +64%
NMERB
338
New Mexico Educational Retirement Board
New Mexico
$9.11M -$1.64M -25,600 -13%
LAM
339
Lebenthal Asset Management
New York
$9.07M +$416K +6,477 +4%
SI
340
Stephens Inc
Arkansas
$9.03M +$2.1M +32,730 +24%
AIP
341
ARS Investment Partners
New York
$9.03M +$1.99K +31 +0%
IA
342
Icon Advisers
Colorado
$8.99M +$3.47M +54,000 +48%
SAM
343
Securian Asset Management
Minnesota
$8.94M +$106K +1,653 +1%
NMIMC
344
Northwestern Mutual Investment Management Company
Wisconsin
$8.91M +$6.53M +101,590 +159%
DSI
345
Daiwa SB Investments
Japan
$8.82M -$11.6K -180 -0.1%
WAM
346
World Asset Management
Michigan
$8.79M +$214K +3,335 +2%
CA
347
CapWealth Advisors
Tennessee
$8.76M -$331K -5,153 -3%
DILH
348
Dai-ichi Life Holdings
Japan
$8.75M -$5.78M -90,045 -36%
TG
349
TCW Group
California
$8.71M -$319K -4,965 -3%
ONB
350
Old National Bancorp
Indiana
$8.66M -$1.65M -25,630 -14%

BMY Hedge Fund Activity: Q3 2016 in Review

1,523 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb (BMY) for Q3 2016, worth a combined $63.3B — down 30% from $90.9B a quarter earlier.

Sellers outnumbered buyers: 147 funds closed out of BMY and 110 opened new positions — a net loss of 37 holders — while 548 trimmed existing stakes and 663 added.

The largest buyer was Wellington Management Group, adding an estimated $437M. The largest seller was T. Rowe Price Associates, cutting an estimated $1.74B.

  • 1,523 institutional investors held Bristol-Myers Squibb (BMY) as of Q3 2016, down from 1,577 in Q2 2016.
  • Funds reported $63.3B of Bristol-Myers Squibb stock for Q3 2016, down 30% quarter-over-quarter.
  • 110 funds opened new Bristol-Myers Squibb positions in Q3 2016 and 147 closed out, a net change of -37 holders.
  • The largest Bristol-Myers Squibb buyer in Q3 2016 was Wellington Management Group, an estimated $437M added.
  • The largest Bristol-Myers Squibb seller in Q3 2016 was T. Rowe Price Associates, an estimated $1.74B sold.

Based on aggregated 13F filings for Q3 2016.